EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Beyond Glucose—Rethinking Prediabetes for Precision Prevention

Robert Wagner iD, Elizabeth Selvin iD, Ratika Sehgal, Katsiaryna Prystupa, Shivani Misra iD, Andreas Fritsche iD, Martin Heni iD

Diabetes Care · 01.02.2026 · 49 (2) · 226-235

DOI: 10.2337/dci25-0054 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes Care, online erschienen am 11.09.2025. Verfasst von Robert Wagner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetology, Medical Faculty, and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, G…. Hauptthemen laut MEDLINE: Prediabetic State, Blood Glucose. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Bundesministerium für Bildung und Forschung, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prediabetes affects more than one-third of U.S. adults, yet represents a biologically heterogeneous state that is only partly captured by traditional glycemic categories (impaired fasting glucose, impaired glucose tolerance, or borderline elevated HbA1c). Leveraging unsupervised clustering in comprehensively phenotyped cohorts has identified six reproducible prediabetes subtypes integrating insulin sensitivity, insulin secretion, visceral and hepatic fat, and genetic risk. Three high-risk subtypes (progressing prediabetes with fatty liver, progressing prediabetes with β-cell failure, and slow progressors with hyperinsulinemic insulin resistance) show distinct trajectories toward diabetes and unique complication patterns. For example, “slow progressors” develop albuminuria and face excess mortality, despite only modest glycemic deterioration over 10–15 years, showing that complications can arise before diabetes diagnosis. Recognizing these subtypes sharpens risk stratification and opens a path toward precision prevention. Intensive lifestyle modification and bariatric surgery offer the greatest glycemic benefit in the fatty liver subtype, whereas early pharmacologic β-cell protection may be required for the β-cell failure cluster. GLP-1–based therapies offer promising subtype-specific options and should be tested in randomized controlled studies. Future prediabetes intervention trials should move beyond diabetes incidence as the sole end point and systematically evaluate kidney, nerve, eye, and cardiovascular outcomes. While testing for long-term clinical end points might not be feasible in studies where individuals with prediabetes are recruited, the use of surrogate end points could facilitate the assessment of early complications. Such complication-focused, subtype-guided studies will determine whether early, tailored therapy can halt tissue damage and reduce the public health burden linked to prediabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prediabetic StateBlood GlucoseHumansInsulin Resistance

Substanzen

Blood Glucose

Autor:innen und Institutionen

  • Department of Endocrinology and Diabetology, Medical Faculty, and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
  • Division of Endocrinology and Diabetology, Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
  • Department of Metabolism, Digestion & Reproduction, Imperial College London, and Department of Diabetes and Endocrinology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, U.K.

ORCID-Profile: Robert Wagner, Elizabeth Selvin, Shivani Misra, Andreas Fritsche, Martin Heni

Förderung

  • Bundesministerium für Bildung und Forschung
  • European Research Council

Zitieren

APA

Wagner, R., Selvin, E., Sehgal, R., Prystupa, K., Misra, S., Fritsche, A., & Heni, M. (2026). Beyond Glucose—Rethinking Prediabetes for Precision Prevention. Diabetes Care, 49(2), 226-235. https://doi.org/10.2337/dci25-0054

Vancouver

Wagner R, Selvin E, Sehgal R, Prystupa K, Misra S, Fritsche A, et al. Beyond Glucose—Rethinking Prediabetes for Precision Prevention. Diabetes Care. 2026;49(2):226-235. doi:10.2337/dci25-0054

BibTeX
@article{Wagner2026,
  author = {Wagner, Robert and Selvin, Elizabeth and Sehgal, Ratika and Prystupa, Katsiaryna and Misra, Shivani and Fritsche, Andreas and Heni, Martin},
  title = {Beyond Glucose—Rethinking Prediabetes for Precision Prevention},
  journal = {Diabetes Care},
  year = {2026},
  volume = {49},
  number = {2},
  pages = {226--235},
  doi = {10.2337/dci25-0054}
}
Kostenlos starten →